stockportfolio.pro
AstraZeneca PLC (AZN)
Healthcare · Drug Manufacturers - General · NYSE
AstraZeneca PLC revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $44.35B | $45.81B | $54.07B | $58.74B |
| Gross profit | $31.96B | $37.54B | $43.87B | $48.11B |
| Net income | $3.29B | $5.96B | $7.04B | $10.22B |
| Net margin | 7.4% | 13.0% | 13.0% | 17.4% |
Source: AstraZeneca PLC SEC filings (10-K).
What growth is priced into AZN stock?
At today's market cap of $281.06B, AstraZeneca PLC is priced for free-cash-flow growth of about 14.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $8.67B from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of AstraZeneca PLC financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AZN in your portfolio →
AstraZeneca PLC financial history by metric
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC — frequently asked questions
What is AstraZeneca PLC's revenue?
AstraZeneca PLC (AZN) reported revenue of $58.74B for fiscal year 2025, up 8.6% from the prior year, according to its SEC filings.
Is AstraZeneca PLC profitable?
Yes. AZN earned net income of $10.22B in fiscal 2025, a net margin of 17.4%.
What is AZN's P/E ratio?
AstraZeneca PLC trades at a price-to-earnings ratio of about 27.3 based on the latest data in our nightly-refreshed cache.
How fast is AstraZeneca PLC growing?
AZN's revenue grew at roughly 9.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AstraZeneca PLC have?
As of fiscal year 2025, AZN carried roughly $27.35B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AstraZeneca PLC's gross margin?
AZN's gross margin was 81.9% in fiscal 2025 — gross profit of $48.11B on revenue of $58.74B.
What is AstraZeneca PLC's market cap?
AstraZeneca PLC (AZN) has a market capitalization of about $281.06B, based on the latest data in our nightly-refreshed cache.
When does AstraZeneca PLC's fiscal year end?
AZN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into AZN stock?
At today's market cap of $281.06B, AstraZeneca PLC is priced for free-cash-flow growth of about 14.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $8.67B from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from AstraZeneca PLC's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.